Lung cancer: open trials in Hong Kong

• NCT05920356

  A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  Trial Treatment · Phase 3 · Amgen

  Queen Mary Hospital, The University of Hong Kong, Hong Kong · Queen Elizabeth Hospital - Hong Kong, Kowloon · Princess Margaret Hospital, Kowloon

  Registry updated 2026-11-06

• NCT06881784

  Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  Trial Treatment · Phase 3 · Revolution Medicines, Inc.

  Hong Kong United Oncology Centre, Hong Kong · Queen Mary Hospital, Hong Kong · Princess Margaret Hospital, Lai Chi Kok · The Chinese University of Hong Kong, Shatin

  Registry updated 2026-11-06

• NCT07699328

  A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

  Trial Treatment · Phase 1/2 · Voronoi, Inc

  Prince of Wales Hospital, Hong Kong · Queen Mary Hospital, Hong Kong

  Registry updated 2026-11-06

• NCT06793215

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  Trial Treatment · Phase 3 · Hoffmann-La Roche

  Queen Mary Hospital, Hong Kong · Tuen Mun Hospital, Hong Kong · Queen Elizabeth Hospital Department of Clinical Oncology, Kowloon · Prince of Wales Hosp, Shatin

  Registry updated 2026-11-05

• NCT07361497

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  Trial Treatment · Phase 3 · Bristol-Myers Squibb

  Queen Mary Hospital, Hksar · Shatin · Tuenmen

  Registry updated 2026-11-05

• NCT06452277

  A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  Trial Treatment · Phase 3 · Bayer

  Queen Elizabeth Hospital Hong Kong, Hong Kong · Prince of Wales Hospital, Hong Kong · Queen Mary Hospital, Hong Kong · Hong Kong United Oncology Centre, Kowloon

  Registry updated 2026-11-04

• NCT06706076

  A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

  Trial Treatment · Phase 1/2 · BlossomHill Therapeutics

  Queen Mary Hospital, Hong Kong · Prince of Wales Hospital, Shatin

  Registry updated 2026-11-04

• NCT07492680

  A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

  Trial Treatment · Phase 2 · Bristol-Myers Squibb

  Hksar · Shatin

  Registry updated 2026-11-04

• NCT06667908

  A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

  Trial Treatment · Phase 2 · Johnson & Johnson Enterprise Innovation Inc.

  Prince of Wales Hospital, Shatin

  Registry updated 2026-11-03

• NCT07185997

  Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

  Trial Treatment · Phase 3 · ArriVent BioPharma, Inc.

  Humanity and Health Clinical Trial Centre, Central · Queen Mary Hospital, Hong Kong · Prince of Wales Hospital, Shatin

  Registry updated 2026-11-02

• NCT07195695

  Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  Trial Treatment · Phase 3 · Boehringer Ingelheim

  Prince of Wales Hospital-Hong Kong-20715, Hong Kong · Queen Elizabeth Hospital-Hong Kong-51727, Hong Kong · Princess Margaret Hospital, Hong Kong · Queen Mary Hospital, Hong Kong

  Registry updated 2026-11-02

• NCT07431827

  MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

  Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC

  Tuen Mun Hospital (Site 3102), Hong Kong · Queen Mary Hospital (Site 3100), Hong Kong

  Registry updated 2026-11-02

• NCT04613596

  Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  Trial Treatment · Phase 2/3 · Mirati Therapeutics Inc.

  Humanity & Health Clinical Trial Centre, Central · Pamela Youde Nethersole Eastern Hospital, Chai Wan · Queen Mary Hospital - Hong Kong, Hong Kong · Queen Elizabeth Hospital - Hong Kong, Kowloon

  Registry updated 2026-10-30

• NCT04886804

  Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

  Trial Treatment · Phase 1 · Boehringer Ingelheim

  Prince of Wales Hospital-Hong Kong-20715, Hong Kong · Queen Mary Hospital, Hong Kong

  Registry updated 2026-10-28

• NCT06747585

  A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors

  Trial Treatment · Phase 1/2 · Alentis Therapeutics AG

  Chinese University of Hong Kong - Prince of Wales Hospital, Shatin

  Registry updated 2026-10-28

• NCT07472517

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  Trial Treatment · Phase 3 · Boehringer Ingelheim

  Queen Mary Hospital, Hong Kong · Prince of Wales Hospital-Hong Kong-20715, Shatin

  Registry updated 2026-10-28

• NCT06875310

  A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

  Trial Treatment · Phase 3 · Mirati Therapeutics Inc.

  Queen Mary Hospital, Hksar

  Registry updated 2026-10-27

• NCT06899126

  Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

  Trial Treatment · Phase 3 · Daiichi Sankyo

  The University of Hong Kong, Hong Kong · Queen Elizabeth Hospital, Hong Kong · The Chinese University of Hong Kong, Shatin · Gleneagles Hospital Hong Kong, Wong Chuk Hang

  Registry updated 2026-10-23

• NCT07063745

  A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  Trial Treatment · Phase 2/3 · Bristol-Myers Squibb

  Queen Mary Hospital, Hksar · Shatin

  Registry updated 2026-10-23

• NCT05099172

  First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

  Trial Treatment · Phase 1/2 · Bayer

  Prince of Wales Hospital, Hong Kong · Queen Mary Hospital, Hong Kong · Hong Kong United Oncology Centre, Kowloon

  Registry updated 2026-10-21

• NCT06669104

  Thoracic Surgery by the Medtronic Hugo™ Robotic System

  Research · Chinese University of Hong Kong

  Prince of Wales Hospital, Hong Kong

  Registry updated 2026-10-21

• NCT07256457

  Postoperative Pulmonary Function Assessment Based on Deep Learning Study

  Trial Treatment · Chinese University of Hong Kong

  Prince of Wales Hospital, Shatin

  Registry updated 2026-10-21

• NCT07722182

  Navigation Bronchoscopy Guided Microwave Ablation Versus SBRT in Early NSCLC

  Trial Treatment · Phase 2 · Chinese University of Hong Kong

  Prince of Wales Hospital, Hong Kong

  Registry updated 2026-10-21

• NCT07741344

  Study of Robotic Assisted/Image Guided Electromagnetic Navigation Bronchoscopic Therapies and Surgery in Stage IA NSCLC

  Trial Treatment · Phase 2 · Chinese University of Hong Kong

  Prince of Wales Hospital, Hong Kong

  Registry updated 2026-10-21

• NCT06312137

  A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

  Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC

  Queen Mary Hospital (Site 3400), Hksar · Hong Kong United Oncology Centre (Site 3403), Kowloon · Queen Elizabeth Hospital (Site 3402), Yau Ma Tei

  Registry updated 2026-10-15

All Lung cancer trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error